Trisha Parikh, PharmD, MBA
Cern Corporation, Inc. / The Cern Device™/ CernDevice.com
1. The Frontline Clinical Reality: Misdiagnosis, Over-
Prescribing, and Prescriptive Obstacles
As a clinical pharmacist, I regularly observe the challenges patients and prescribers face when
managing recurrent vaginal symptoms. Bacterial vaginosis (BV) and vulvovaginal candidiasis
(VVC, or fungal vaginosis including RVVC, recurrent vulvovaginal candidiasis) are two of the
most common lower genital tract complaints in adult women, yet their clinical presentation often
overlaps significantly. Key diagnostic and treatment obstacles include:
● High Misdiagnosis Rates & Diagnostic Uncertainty: Empirical treatment based solely
on clinical symptoms (such as discharge characteristics or itch) frequently leads to
misdiagnosis. A major clinical trap occurs when a patient presents with symptoms of BV
or yeast, but without point-of-care wet mount microscopy or molecular testing (PCR),
fungal vaginitis is mistaken for BV or vice-versa. The high rate of empirical
overprescribing was highlighted in a massive clinical dataset of 149,934 female patients
experiencing vulvovaginal candidiasis symptoms, which revealed that over 60% of the
individuals lacked any diagnostic testing codes prior to therapy (Centers for Disease
Control and Prevention [CDC], 2022) [PMC9049332]. Despite this lack of diagnostic
validation, 16.8% of these suspected yeast patients were blindly prescribed systemic
antibacterial medications, demonstrating a heavy clinical reliance on symptom guesswork
that drives improper treatment (CDC, 2022) [PMC9049332]. When providers rely entirely
on these subjective physical signs to differentiate between the two conditions, the margin
of error is profound. A comprehensive medical review evaluating the historical limitations
of vaginitis diagnostics confirmed that traditional, symptom-based clinical impressions are
highly unreliable, showing that the overall misdiagnosis rate approaches 50% across
primary care and gynecological settings (Brown & Drexler, 2020) [PMC7591372]. This
review establishes that because the physical presentations of bacterial vaginosis and
yeast heavily overlap, relying on a provider’s visual assessment or standard pH testing
routines carries a persistent 50% error rate (Brown & Drexler, 2020) [PMC7591372].
Furthermore, this diagnostic failure severely impacts patients with concurrent mixed
infections; when both conditions exist simultaneously, empirical guesswork routinely
misses the secondary infection entirely, leaving patients partially or completely mistreated
(Brown & Drexler, 2020) [PMC7591372].
● Empiric Overuse of Antibiotics: When fungal infections are misdiagnosed as BV,
patients are inappropriately prescribed broad-spectrum oral or topical antibiotics (e.g.,
metronidazole or clindamycin). Antibiotic exposure eradicates protective Lactobacillus
species, altering the vaginal microbiome and often triggering or exacerbating a secondary
fungal overgrowth.
● Simultaneous “Cover-All” Prescribing: When diagnostic certainty is low and clinicians
wish to avoid treatment delays or repeated visits, it is not uncommon in real-world practice
for prescribers to simultaneously write orders for both an oral antifungal (e.g., fluconazole)
and an antibacterial agent (e.g., metronidazole). While this dual strategy attempts to cover
all bases, it increases drug exposure, side-effect burdens, and healthcare costs without
addressing root causes.
● Drug-Drug Interactions & Severe Contraindications: Standard pharmacotherapy
carries significant pharmacological risks:
○ Metronidazole: Requires strict alcohol avoidance due to severe disulfiram-like
reactions and presents frequent gastrointestinal intolerance.
○ Fluconazole: A strong CYP3A4 and CYP2C9 inhibitor, raising toxicity risks when
combined with common co-medications (e.g., statins, warfarin, or certain
antiepileptics).
○ Pregnancy & Recurrence Limitations: Oral fluconazole is heavily restricted or
contraindicated during pregnancy—particularly in high or repeated doses—due to
documented clinical risks of spontaneous abortion and congenital anomalies (CDC,
2021). This restriction severely limits safe options for pregnant patients. It creates a
severe clinical bottleneck for managing Recurrent Vulvovaginal Candidiasis (RVVC)
and mixed infections, forcing a reliance on prolonged, 7-day topical azole regimens
that suffer from patient non-adherence. (Mencacci et al., 2024). [1, 2, 3, 4, 5].
○ Bacterial Vaginosis (BV): While oral metronidazole or clindamycin are standard
options used to treat symptomatic BV during pregnancy to prevent severe
complications like preterm birth, these antibiotics carry strict clinical hurdles
(Centers for Disease Control and Prevention [CDC], 2021). Oral medications
frequently cause intense gastrointestinal distress, nausea, and a severe metallic
taste, which heavily impacts patient compliance (Geer & Klega, 2025). In fact,
clinical compliance tracking reveals that as many as 50% of patients do not
complete a full 7-day course of metronidazole due to these side effects
(Solosec Healthcare, 2024). This widespread non-compliance leaves patients with
sub-therapeutic drug levels, failing to fully clear the bacteria and directly driving high
rates of persistent or recurrent BV infections (Solosec Healthcare, 2024).
● Antimicrobial Resistance & High Recurrence: Recurrent BV and VVC are extremely
common. Repeated cycles of traditional antimicrobials contribute to treatment refractory
cases, biofilm formation (did not know this. (particularly with Gardnerella vaginalis), and
antifungal resistance (e.g., non-albicans Candida species like Candida glabrata and
Candida krusei.
● Antimicrobial Resistance & High Recurrence: Recurrent episodes of bacterial
vaginosis (BV) and vulvovaginal candidiasis (VVC) are extremely common.
Repeated, blind cycles of traditional antimicrobials directly accelerate treatment-
refractory cases through two distinct microbiological mechanisms:
○ Bacterial Biofilm Formation: In recurrent BV, the core pathogen Gardnerella
vaginalis initiates the formation of a dense, adherent, polymicrobial biofilm
on the vaginal epithelium [PMC10281382]. This sticky matrix physically
shields the bacteria and allows the pathogens to tolerate up to five times the
normal concentrations of protective vaginal acids [Journals.sagepub.com].
Because conventional antibiotics like metronidazole or clindamycin cannot
fully penetrate or dissolve this protective structure, the biofilm remains
structurally intact even after a patient completes a standard therapy course,
directly driving rapid clinical relapse [PMC4718981].
○ Fungal Antifungal Resistance: In recurrent yeast infections, repeated
exposure to over-the-counter and prescription azoles drives a clinical shift
away from sensitive Candida albicans toward highly resistant non-albicans
species [PMC787119]. Specifically, Candida glabrata and Candida krusei
have become major clinical hurdles [Diabetesjournals.org]. Candida glabrata
is notoriously difficult to identify under a standard office microscope and
exhibits high resistance to standard fluconazole [Diabetesjournals.org].
Simultaneously, Candida krusei is recognized as a multidrug-resistant
pathogen that is completely, intrinsically resistant to fluconazole, rendering
standard single-dose oral therapies entirely useless and forcing clinicians to
rely on aggressive, non-fluconazole or echinocandin treatment strategies
[PMC2238087, WHO].
● High-Risk Patient Populations: Diabetic patients with elevated glycemic levels face
chronic candida colonization. Similarly, immunocompromised individuals, patients taking
chronic corticosteroids, or those on oral contraceptives experience persistent alterations
in vaginal pH and glycogen availability, driving non-stop recurrence.
2. Barriers to Access: Access, Cost, and Health
System Friction
Beyond pharmacological limitations, the traditional care delivery pathway presents significant
friction for women suffering from lower tract symptoms:
● Care Delays & Inconvenience: Securing an in-person gynecology or primary care
appointment often requires days or weeks, forcing patients to endure debilitating
discomfort or rely on ineffective over-the-counter (OTC) remedies.
● Telehealth Limitations: While telehealth improves speed of access, virtual care relies
almost entirely on self-reported patient history without physical examination or lab
diagnostics, further elevating the probability of misdiagnosis and inappropriate empiric
prescriptions.
● Financial Burden: Accumulated co-pays for doctor visits, specialized lab tests, virtual
consultations, and multiple prescription refills create a recurring financial drain on patients
and health systems alike.
3. How Cern Can Transform the Market Landscape
Cern’s non-pharmacological, targeted technological approach represents a paradigm shift in
how vaginal health and recurrent dysbiosis are managed. By offering a direct microbicidal
solution that eliminates reliance on systemic or topical antimicrobial drugs, Cern addresses the
fundamental flaws of current clinical practice:
● Elimination of Chemical & Pharmacological Risks: Cern’s low level microbicidal light
approach, avoids drug-drug interactions, CYP enzyme inhibition, disulfiram reactions, and
pregnancy contraindications, opening a safe care pathway for high-risk, pregnant, and
complex polypharmacy patients.
● Bypassing Antimicrobial Resistance: Physical/phototherapy-based mechanism of
action prevents pathogen mutation and biofilm resistance, offering what may be a
sustainable solution for patients with chronic, recurrent BV or refractory fungal vaginitis.
● Disrupting the Diagnostic-Prescription Loop: By providing effective local therapy,
Cern reduces the need for speculative dual-prescribing (“shotgun approach”) and
eliminates the cascade of antibiotic-induced secondary infections.
● Empowering Patient-Centered Care: Cern shifts care away from high-cost clinic visits
and speculative virtual prescribing toward convenient, effective, and lower-cost
management—drastically lowering lifetime healthcare expenditure and improving overall
quality of life for women.
References
Brown, H., & Drexler, M. (2020). Improving the diagnosis of vulvovaginitis: Perspectives to align practice,guidelines, and awareness. Population Health Management, 23(S1), S3-S10.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7591372/ [PMC7591372]
Centers for Disease Control and Prevention. (2022). Possible misdiagnosis, inappropriate empiric
treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis—United States, 2018. MMWR. Morbidity and Mortality Weekly Report, 71(15), 541–545. nih.gov [PMC9049332]
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR. Recommendations and Reports, 70(4), 1–187. https://www.cdc.gov/std/treatment- guidelines/candidiasis.htm [1]
Geer, K., & Klega, A. (2025). Vaginitis: Diagnosis and treatment. American Family Physician, 112(5),
450–458. aafp.org
Machado, D., Castro, J., Palmeira-de-Oliveira, A., Martinez-de-Oliveira, J., & Cerca, N. (2016).
Progresses in vaginal microflora physiology and implications for bacterial vaginosis. Women’s Health,
12(1), 95-107. https://journals.sagepub.com/doi/10.2217/whe.16.5
Marrazzo, J. M., & Sobel, J. D. (2023). Fighting polymicrobial biofilms in bacterial vaginosis. The Lancet
Microbe, 4(6), e388-e389. https://pmc.ncbi.nlm.nih.gov/articles/PMC10281382/
Mencacci, A., Di Sante, L., Roselletti, E., & Perito, S. (2024). Fluconazole-resistant vulvovaginal
candidosis: An update on current management and antibiotic stewardship. Pathogens, 13(12), 1052.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11678211/ [1]
O’Laughlin, D. J., & McCoy, R. G. (2023). Diabetes and vulvovaginal conditions. Clinical Diabetes, 41(3),
458-464. diabetesjournals.org
Solosec Healthcare. (2024). Bacterial vaginosis management: Treatment guidelines, compliance, and
recurrence risks. Symbiomix Therapeutics. solosechcp.com
World Health Organization. (2025). Candidiasis (yeast infection): Fungal pathogens and multidrug-
resistant species. WHO Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/candidiasis-
(yeast-infection)